ACHIEVE LIFE SCIENCES, INC.
ACHVNasdaq
$6.27
↑ +5.2%Jul 17 close · end-of-day
Price
1Y↑ +133.1%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$334.7M
Enterprise Value
$305.4M
P/E
—
P/S
—
P/B
31.3
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$52.0M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-486.9%
ROIC
—
Debt / Equity
—
Net Cash
$29.3M
Return 1Y
+128.0%
Company profile
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company is based in Vancouver, Canada and has license agreements with Sopharma AD and University of Bristol.
- CEO
- John A. Bencich
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 20
- Headquarters
- Washington
- Website
- achievelifesciences.com
Management & directors
- Oki Mark KChief Financial Officer
- Stewart Richard AlistairChief Executive Officer
- Jacobs CindyPresident & CMO
- Wann JerryPrincipal Accounting Officer
- Xinos JaimeChief Commercial Officer
Roles derived from SEC Form 4 filings.
Earnings
ACHV Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.19↓ -48.6%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | — | — | — | — | — | — |
| Net income | -$14.7M | -$33.2M | -$42.4M | -$29.8M | -$39.8M | -$54.6M |
| Diluted EPS | -$5.42 | -$4.08 | -$4.00 | -$1.50 | -$1.24 | -$1.25 |
| Operating cash flow | -$13.5M | -$29.4M | -$37.6M | -$24.5M | -$29.8M | -$49.5M |
| Free cash flow | -$13.5M | — | — | -$24.5M | — | -$49.5M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — |
| Line item | Q3 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q3 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | — | — | — | — | — | — | — | — |
| Net income | -$8.5M | -$12.5M | -$12.4M | -$12.8M | -$12.7M | -$14.4M | -$14.7M | -$10.2M |
| Diluted EPS | -$0.25 | -$0.36 | -$0.37 | -$0.37 | -$0.37 | -$0.28 | -$0.23 | -$0.19 |
| Operating cash flow | -$4.9M | -$10.4M | -$9.2M | -$11.1M | -$9.1M | -$11.3M | -$18.0M | -$6.9M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jul 10, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2025-09-18 | Stewart Richard Alistair· Chief Executive Officer | Sale | 129,501 | $2.92 | $378,142.92 | filing |
| 2025-09-18 | Oki Mark K· Chief Financial Officer | Sale | 50,060 | $2.92 | $146,175.20 | filing |
| 2025-09-18 | Stewart Richard Alistair· Chief Executive Officer | Option exercise | 297,500 | $0.00 | $0.00 | filing |
| 2025-09-18 | Oki Mark K· Chief Financial Officer | Option exercise | 168,000 | $0.00 | $0.00 | filing |
| 2025-09-04 | KING THOMAS BRAXTON | Sale | 139,858 | $2.77 | $387,406.66 | filing |
| 2025-09-04 | JACOBS CINDY· President & CMO | Sale | 27,629 | $2.77 | $76,532.33 | filing |
| 2025-09-04 | Xinos Jaime· Chief Commercial Officer | Sale | 20,854 | $2.77 | $57,765.58 | filing |
| 2025-09-04 | Wann Jerry· Principal Accounting Officer | Sale | 14,070 | $2.77 | $38,973.90 | filing |
| 2025-09-04 | KING THOMAS BRAXTON | Option exercise | 455,000 | $0.00 | $0.00 | filing |
| 2025-09-04 | JACOBS CINDY· President & CMO | Option exercise | 110,000 | $0.00 | $0.00 | filing |
| 2025-09-04 | Xinos Jaime· Chief Commercial Officer | Option exercise | 69,000 | $0.00 | $0.00 | filing |
| 2025-09-04 | Wann Jerry· Principal Accounting Officer | Option exercise | 34,100 | $0.00 | $0.00 | filing |
Latest 12 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.